$COR · Cencora, Inc.
Cencora filed an 8-K on October 21, 2026, announcing two items: (1) a definitive agreement to acquire American Oncology Network for a $2.4 billion enterprise value ($2.3B at close plus up to $100M in CVRs), with Cencora expecting to pay ~$1.7B for 75% ownership assuming a 25% equity rollover; and (2) updated FY2026 adjusted diluted EPS guidance raised to at least $17.90, the high end of the prior $17.75–$17.95 range. The AON deal adds 350+ oncology providers across 21 states and is expected to be EPS-accretive in year two post-close.
- Cencora will acquire AON for a $2.4B enterprise value: $2.3B at close plus up to $100M in contingent value rights.
- Cencora already holds ~4% of AON; expects to pay ~$1.7B cash at close for 75% ownership assuming 25% equity rollover.
- FY2026 adjusted diluted EPS guidance raised to at least $17.90, the high end of the prior $17.75–$17.95 range.
- The acquisition is expected to be accretive to adjusted diluted EPS in the second year post-closing.
- AON brings 350+ oncology providers across 21 states, expanding Cencora's physician-led MSO platform into 12 new states.
Extended-hours trading shows COR at $334.34, down 2.60% from the regular-session close of $343.27, suggesting initial investor caution around the $2.4B deal price and integration risk despite the guidance raise.
A $2.4B oncology-platform acquisition plus a guidance raise to the top of the range makes this a double-catalyst event for a $65B+ market-cap pharmaceutical distributor.
The deal extends Cencora's push beyond pharmaceutical distribution into provider services, following its prior oncology MSO investments. The community oncology consolidation trend continues as scaled platforms seek to capture value-based care economics.
Regulatory clearance and AON stockholder approval are required to close; failure to obtain either could scuttle the deal. Integration risk is material — Cencora must absorb 350+ providers across 21 states while retaining key physicians and maintaining practice relationships.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.